60% of Indian breast cancer patients diagnosed at late stages, experts warn

In Delhi, at a healthcare conference focused on women's health, a surgical oncologist laid out a troubling arithmetic: six out of every ten Indian women who come seeking treatment for breast cancer are already in its later stages when they arrive. Dr. Geeta Kadayaprath, who works at Apollo Athenaa Women's Cancer Centre, was speaking at the Mission Namo Shakti session during NewsX's We Women Want Conclave when she offered this observation about the state of cancer detection across the country.

The paradox, though, is that India has not been standing still. The absolute number of breast cancer cases has climbed over the years, yet the medical infrastructure has advanced in parallel—newer diagnostic technologies, more refined treatment approaches, better protocols for managing the disease. The problem is not that medicine has stalled. The problem is distribution.

At Kadayaprath's own hospital, the picture looks radically different. Nearly seven out of ten patients arrive with early-stage diagnoses. The difference between 60 percent late-stage detection nationally and 70 percent early-stage detection at a private Delhi facility is not a matter of biology or bad luck. It is a matter of who can afford to walk through the door. Women with resources—those who can pay for private care, who live in cities where hospitals exist, who have heard about screening—are catching their cancers when they are still treatable. Women without those advantages are not.

The gap exists because awareness and access move together. Private hospitals serve populations that have already heard about breast cancer screening, that have the money to pursue it, that live near enough to a facility to make it possible. Rural India, by contrast, remains largely in the dark. When technicians from the Namo Shakti Initiative—a program launched by Rajya Sabha MP Kartikeya Sharma that deploys AI-enabled mobile screening units to remote villages—arrive in communities, they encounter women who have never been tested, who do not understand what screening is, who have no framework for thinking about prevention.

The Namo Shakti technicians who spoke at the same session—Darshana Rani, Anjali Devi, and Balbir Kaur—reported that the response from villages has been encouraging once the units arrive. Women come. They get tested. But the baseline is so low that even encouraging response means starting from near zero. The technicians noted a clear pattern: as awareness spreads, more women seek testing. But awareness itself is the bottleneck. In villages, it barely exists.

What this means in practical terms is that a woman in a rural area or a lower-income urban neighborhood is far more likely to discover her cancer only after it has begun to spread, only after symptoms have become impossible to ignore, only when the disease is harder to treat and survival rates have already declined. A woman in a private hospital in Delhi is far more likely to catch it early, when options are broader and outcomes are better. The same disease. The same country. Radically different fates, determined largely by geography and money.

The Namo Shakti Initiative represents an attempt to narrow that gap—to bring screening technology to places where it does not currently exist, to build awareness where there is none. But the scale of the problem is immense. Six out of ten women arriving for treatment are already late. That is not a small number. That is the majority. And it suggests that even as technology advances and private hospitals perfect their protocols, the real work—the unglamorous, difficult work of reaching women who have never been screened, in places where hospitals are far away—has barely begun.